JP2021504494A - アデノシン誘導体を含む網膜疾患または視神経疾患の予防及び治療用薬学的組成物 - Google Patents
アデノシン誘導体を含む網膜疾患または視神経疾患の予防及び治療用薬学的組成物 Download PDFInfo
- Publication number
- JP2021504494A JP2021504494A JP2020549534A JP2020549534A JP2021504494A JP 2021504494 A JP2021504494 A JP 2021504494A JP 2020549534 A JP2020549534 A JP 2020549534A JP 2020549534 A JP2020549534 A JP 2020549534A JP 2021504494 A JP2021504494 A JP 2021504494A
- Authority
- JP
- Japan
- Prior art keywords
- chemical formula
- treatment
- prevention
- compound represented
- optic nerve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 Cc1nc(*)nc2c1nc[n]2[C@@](C1O)NCC1O Chemical compound Cc1nc(*)nc2c1nc[n]2[C@@](C1O)NCC1O 0.000 description 3
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (22)
- 前記網膜疾患は、糖尿病性網膜症または加齢黄斑変性であることを特徴とする請求項1に記載の網膜疾患の予防または治療用薬学組成物。
- 前記網膜疾患は、糖尿病性網膜症または加齢黄斑変性であることを特徴とする請求項4に記載の網膜疾患の予防または治療用経口投与剤。
- 前記経口投与剤は、メチルセルロース(MC)、ジメチルスルホキシド(DMSO)、ポリエチレングリコール(PEG)、及び蒸留水からなる群から選択される1つ以上を含む賦形剤をさらに含むことを特徴とする請求項4に記載の網膜疾患の予防または治療用経口投与剤。
- 前記賦形剤は、0.5wt%メチルセルロースを含むことを特徴とする請求項6に記載の網膜疾患の予防または治療用経口投与剤。
- 前記化学式1で表される化合物またはその薬学的に許容可能な塩は、粉末状にカプセル内に充填されることを特徴とする請求項4に記載の網膜疾患の予防または治療用経口投与剤。
- 前記網膜疾患は、糖尿病性網膜症または加齢黄斑変性であることを特徴とする請求項10に記載の網膜疾患の予防または治療用点眼剤。
- 前記視神経疾患は、虚血性視神経症、外傷性視神経症及び圧迫性視神経症からなる群から選択されることを特徴とする請求項12に記載の視神経疾患の予防または治療用薬学組成物。
- 前記視神経疾患は、虚血性視神経症、外傷性視神経症及び圧迫性視神経症からなる群から選択されることを特徴とする請求項15に記載の視神経疾患の予防または治療用経口投与剤。
- 前記経口投与剤は、メチルセルロース(MC)、ジメチルスルホキシド(DMSO)、ポリエチレングリコール(PEG)、及び蒸留水からなる群から選択される1つ以上を含む賦形剤をさらに含むことを特徴とする請求項15に記載の視神経疾患の予防または治療用経口投与剤。
- 前記経口投与剤は、0.5wt%メチルセルロースを含むことを特徴とする請求項17に記載の視神経疾患の予防または治療用経口投与剤。
- 前記化学式1で表される化合物またはその薬学的に許容可能な塩は、粉末状にカプセル内に充填されることを特徴とする請求項15に記載の視神経疾患の予防または治療用経口投与剤。
- 前記視神経疾患は、虚血性視神経症、外傷性視神経症及び圧迫性視神経症からなる群から選択されることを特徴とする請求項21に記載の視神経疾患の予防または治療用点眼剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022160407A JP2023011577A (ja) | 2017-11-29 | 2022-10-04 | アデノシン誘導体を含む網膜疾患または視神経疾患の予防及び治療用薬学的組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170161545A KR102007640B1 (ko) | 2017-11-29 | 2017-11-29 | 아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물 |
KR10-2017-0161545 | 2017-11-29 | ||
PCT/KR2018/014943 WO2019107964A1 (ko) | 2017-11-29 | 2018-11-29 | 아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022160407A Division JP2023011577A (ja) | 2017-11-29 | 2022-10-04 | アデノシン誘導体を含む網膜疾患または視神経疾患の予防及び治療用薬学的組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021504494A true JP2021504494A (ja) | 2021-02-15 |
JP7160384B2 JP7160384B2 (ja) | 2022-10-25 |
Family
ID=66665111
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020549534A Active JP7160384B2 (ja) | 2017-11-29 | 2018-11-29 | アデノシン誘導体を含む網膜疾患または視神経疾患の予防及び治療用薬学的組成物 |
JP2022160407A Pending JP2023011577A (ja) | 2017-11-29 | 2022-10-04 | アデノシン誘導体を含む網膜疾患または視神経疾患の予防及び治療用薬学的組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022160407A Pending JP2023011577A (ja) | 2017-11-29 | 2022-10-04 | アデノシン誘導体を含む網膜疾患または視神経疾患の予防及び治療用薬学的組成物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20210361690A1 (ja) |
EP (1) | EP3725317B1 (ja) |
JP (2) | JP7160384B2 (ja) |
KR (1) | KR102007640B1 (ja) |
CN (2) | CN111432822B (ja) |
AU (1) | AU2018374675B2 (ja) |
CA (1) | CA3083398C (ja) |
WO (1) | WO2019107964A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4186514A1 (en) * | 2021-11-24 | 2023-05-31 | Future Medicine Co., Ltd. | Pharmaceutical composition for preventing or treating cholangitis or liver disease caused by cholangitis comprising adenosine derivative |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012125400A1 (en) * | 2011-03-14 | 2012-09-20 | Acorn Biomedical, Inc. | Compositions and methods using adenosine a3 receptor antagonists for the treatment of inflammatory eye diseases |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0028383D0 (en) * | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
CA2665616A1 (en) | 2006-10-06 | 2008-04-17 | The Trustees Of The University Of Pennsylvania | Effective delivery of cross-species a3 adenosine-receptor antagonists toreduce intraocular pressure |
ES2409930T3 (es) | 2007-01-31 | 2013-06-28 | Sanwa Kagaku Kenkyusho Co., Ltd | Agente protector del nervio de la retina o del nervio óptico |
JP5306238B2 (ja) * | 2007-03-07 | 2013-10-02 | エフエム・セラピューティクス・カンパニー・リミテッド | アデノシン誘導体、その合成方法、並びにこれを有効成分として含有する炎症性疾患の予防及び治療用医薬組成物 |
KR101396092B1 (ko) | 2007-03-07 | 2014-05-15 | 미합중국 정부, 디파트먼트 오브 헬쓰 앤드 휴먼 써비스 내셔널 인스티투트 오브 헬쓰 | 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 약학적 조성물 |
US9181253B2 (en) * | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
AU2014239232A1 (en) * | 2013-03-15 | 2015-10-01 | Inotek Pharmaceuticals Corporation | A method of providing ocular neuroprotection |
KR101709307B1 (ko) * | 2016-10-31 | 2017-02-23 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 비알콜성 지방간염, 간섬유증 및 간경변증 예방 및 치료용 약학적 조성물 |
KR101805400B1 (ko) * | 2017-03-21 | 2017-12-07 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물 |
-
2017
- 2017-11-29 KR KR1020170161545A patent/KR102007640B1/ko active IP Right Grant
-
2018
- 2018-11-29 EP EP18883014.5A patent/EP3725317B1/en active Active
- 2018-11-29 AU AU2018374675A patent/AU2018374675B2/en active Active
- 2018-11-29 US US16/767,489 patent/US20210361690A1/en not_active Abandoned
- 2018-11-29 CA CA3083398A patent/CA3083398C/en active Active
- 2018-11-29 CN CN201880077439.0A patent/CN111432822B/zh active Active
- 2018-11-29 WO PCT/KR2018/014943 patent/WO2019107964A1/ko unknown
- 2018-11-29 JP JP2020549534A patent/JP7160384B2/ja active Active
- 2018-11-29 CN CN202210596951.4A patent/CN114886909A/zh active Pending
-
2022
- 2022-07-18 US US17/866,990 patent/US20230095356A1/en active Pending
- 2022-10-04 JP JP2022160407A patent/JP2023011577A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012125400A1 (en) * | 2011-03-14 | 2012-09-20 | Acorn Biomedical, Inc. | Compositions and methods using adenosine a3 receptor antagonists for the treatment of inflammatory eye diseases |
Also Published As
Publication number | Publication date |
---|---|
WO2019107964A1 (ko) | 2019-06-06 |
EP3725317A4 (en) | 2021-08-04 |
CN111432822B (zh) | 2022-07-01 |
US20210361690A1 (en) | 2021-11-25 |
AU2018374675B2 (en) | 2021-10-07 |
EP3725317B1 (en) | 2024-02-07 |
KR102007640B1 (ko) | 2019-08-07 |
CA3083398C (en) | 2022-09-20 |
JP2023011577A (ja) | 2023-01-24 |
EP3725317A1 (en) | 2020-10-21 |
KR20190062894A (ko) | 2019-06-07 |
JP7160384B2 (ja) | 2022-10-25 |
AU2018374675A1 (en) | 2020-06-18 |
CN111432822A (zh) | 2020-07-17 |
CA3083398A1 (en) | 2019-06-06 |
CN114886909A (zh) | 2022-08-12 |
US20230095356A1 (en) | 2023-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7234283B2 (ja) | 翼状片を治療するための組成物及び方法 | |
US7867983B2 (en) | Methods to protect skeletal muscle against injury | |
US5780450A (en) | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage | |
Jenner | Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease | |
RU2470635C2 (ru) | Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза | |
JP5591720B2 (ja) | 抗神経変性疾患剤 | |
JP2007516227A (ja) | ピロール化合物およびその使用 | |
EP2985283B1 (en) | Anti-angiogenesis compound, intermediate and use thereof | |
JP2016507571A (ja) | フッ化インテグリンアンタゴニスト | |
TW200526224A (en) | Short form c-Maf transcription factor antagonists for treatment of glaucoma | |
JP7025094B2 (ja) | ヘテロシクリデンアセトアミド誘導体含有医薬 | |
US20230095356A1 (en) | Pharmaceutical composition comprising adenosine derivative for prevention and treatment of retinal disease or optic nerve disease | |
KR20030016222A (ko) | 수술후 스트레스 예방ㆍ치료제 | |
WO2001021166A1 (en) | Treatment and prevention of hepatic disorders | |
US10537563B2 (en) | Methods for treating ocular disease using inhibitors of CSF-1R | |
RU2791639C2 (ru) | Средство, увеличивающее мозговой кровоток | |
TW201315470A (zh) | 吡咯並喹啉基-吡咯啶-2,5-二酮調製劑類及製備和使用彼等之方法 | |
US20210121518A1 (en) | Her2-targeted peptidomimetics grafted onto multicyclic peptide scaffolds and methods and uses | |
JP2016520610A (ja) | 網膜変性疾患の治療のための組成物及び方法 | |
JP2003221334A (ja) | 糖尿病性合併症の予防・治療剤 | |
Bellashher | Mechanisms of Action of Drugs Lowering Intraocular Pressure of the Eye | |
WO1999023214A1 (en) | Compositions and methods for enhancing cardiac contractility mediated by myocyte p2 purinoceptors and models thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200626 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210601 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220307 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220607 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220622 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20220805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220817 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220906 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221005 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7160384 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |